BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Richard N, Hudson M, Wang M, Gyger G, Proudman S, Stevens W, Nikpour M;  Canadian Scleroderma Research Group (CSRG);  Australian Scleroderma Interest Group (ASIG); Baron M. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. Rheumatology (Oxford). 2019;58:636-644. [PMID: 30517716 DOI: 10.1093/rheumatology/key350] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Luquez-Mindiola A, Atuesta AJ, Gómez-Aldana AJ. Gastrointestinal manifestations of systemic sclerosis: An updated review. World J Clin Cases 2021; 9(22): 6201-6217 [PMID: 34434988 DOI: 10.12998/wjcc.v9.i22.6201] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Soffritti I, D'Accolti M, Ravegnini G, Arcangeletti MC, Maccari C, De Conto F, Calderaro A, Caselli E. Modulation of microRNome by Human Cytomegalovirus and Human Herpesvirus 6 Infection in Human Dermal Fibroblasts: Possible Significance in the Induction of Fibrosis in Systemic Sclerosis. Cells 2021;10:1060. [PMID: 33946985 DOI: 10.3390/cells10051060] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3 Andréasson K, Neringer K, Wuttge DM, Henrohn D, Marsal J, Hesselstrand R. Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation-a prospective, observational study. Arthritis Res Ther 2020;22:230. [PMID: 33023643 DOI: 10.1186/s13075-020-02323-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pamarthy R, Berumen A, Breen-Lyles M, Grover M, Makol A. Comparing Clinical, Imaging, and Physiological Correlates of Intestinal Pseudo-Obstruction: Systemic Sclerosis vs Amyloidosis and Paraneoplastic Syndrome. Clin Transl Gastroenterol 2020;11:e00206. [PMID: 32931184 DOI: 10.14309/ctg.0000000000000206] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Korsten P, Wallbach M, Binder C. Type 2A von Willebrand disease and systemic sclerosis: Vonicog alfa reduced gastrointestinal bleeding. Res Pract Thromb Haemost 2020;4:1230-4. [PMID: 33134789 DOI: 10.1002/rth2.12426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Carr ZJ, Klick J, McDowell BJ, Charchaflieh JG, Karamchandani K. An Update on Systemic Sclerosis and its Perioperative Management. Curr Anesthesiol Rep 2020;:1-10. [PMID: 32904358 DOI: 10.1007/s40140-020-00411-8] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 McMahan ZH. Gastrointestinal involvement in systemic sclerosis: an update. Curr Opin Rheumatol 2019;31:561-8. [PMID: 31389815 DOI: 10.1097/BOR.0000000000000645] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
8 Hughes M, Heal C, Siegert E, Hachulla E, Airó P, Riccardi A, Distler O, Matucci-Cerinic M; EUSTAR Collaborators. Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2020;79:1123-5. [PMID: 32213494 DOI: 10.1136/annrheumdis-2020-217035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nakane S, Umeda M, Kawashiri SY, Mukaino A, Ichinose K, Higuchi O, Maeda Y, Nakamura H, Matsuo H, Kawakami A. Detecting gastrointestinal manifestations in patients with systemic sclerosis using anti-gAChR antibodies. Arthritis Res Ther. 2020;22:32. [PMID: 32085768 DOI: 10.1186/s13075-020-2128-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
10 Quinlivan A, Ross L, Proudman S. Systemic sclerosis: Advances towards stratified medicine. Best Pract Res Clin Rheumatol 2020;34:101469. [PMID: 31973938 DOI: 10.1016/j.berh.2019.101469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
11 Stupalkowska W, Mahler-Araujo B, Bennett J, Gourgiotis S. Spontaneous bowel perforation in the setting of colonic involvement with scleroderma. BMJ Case Rep 2020;13:e233220. [PMID: 31907219 DOI: 10.1136/bcr-2019-233220] [Reference Citation Analysis]
12 Hoffmann-vold A, Volkmann ER. Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches. Journal of Scleroderma and Related Disorders 2021;6:37-43. [DOI: 10.1177/2397198319891282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
13 Zanatta E, Codullo V, Avouac J, Allanore Y. Systemic sclerosis: Recent insight in clinical management. Joint Bone Spine 2020;87:293-9. [PMID: 31568838 DOI: 10.1016/j.jbspin.2019.09.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
14 Michaud M, Catros F, Ancellin S, Gaches F. Mise au point sur les sclérodermies très précoces et précoces. La Revue de Médecine Interne 2019;40:517-22. [DOI: 10.1016/j.revmed.2019.03.327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Morrisroe K, Baron M, Frech T, Nikpour M. Small intestinal bacterial overgrowth in systemic sclerosis. Journal of Scleroderma and Related Disorders 2020;5:33-9. [DOI: 10.1177/2397198319863953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Dein E, Kuo PL, Hong YS, Hummers LK, Mecoli CA, McMahan ZH. Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. Semin Arthritis Rheum. 2019;49:405-410. [PMID: 31202479 DOI: 10.1016/j.semarthrit.2019.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]